J
Jordi Bruix
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 7
Citations - 10062
Jordi Bruix is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Hepatocellular carcinoma & Cancer. The author has an hindex of 6, co-authored 7 publications receiving 9705 citations.
Papers
More filters
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
Josep M. Llovet,Michel Ducreux,Riccardo Lencioni,Adrian M. Di Bisceglie,Jean-Francois J. DuFour,Tim F. Greten,Eric Raymond,Tania Roskams,Vincenzo Mazzaferro,Jordi Bruix,Massimo Colombo,Andrew X. Zhu +11 more
TL;DR: The purpose of this document is to assist physicians, patients, health-care providers, and health-policy makers from Europe and worldwide in the decision-making process according to evidencebased data.
BASIC AND TRANSLATIONAL—BILIARY Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Daniela Sia,Yujin Hoshida,Augusto Villanueva,Sasan Roayaie,Joana Ferrer,Barbara Tabak,Judit Peix,Manel Solé,Victoria Tovar,Clara Alsinet,Helena Cornella,Brandy Klotzle,Christian Cotsoglou,Swan Thung,Josep Fuster,Samuel Waxman,Jordi Bruix,Myron Schwartz,Rameen Beroukhim,Vincenzo Mazzaferro,Josep M. Llovet +20 more
TL;DR: In this paper, the authors performed an integrative genomic analysis of cholangiocarcinoma (ICC) samples from a large series of patients and identified two main biological classes of ICC: the inflammation class (38% of ICCs) is characterized by activation of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation.
Special article Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Jordi Bruix,Morris Sherman,Josep M. Llovet,Michel Beaugrand,Riccardo Lencioni,Andrew K. Burroughs,Erik Christensen,Luigi Pagliaro,Massimo Colombo +8 more
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage q
Victoria Tovar,Clara Alsinet,Augusto Villanueva,Yujin Hoshida,Derek Y. Chiang,Manel Solé,Swan Thung,Susana Moyano,Sara Toffanin,Beatriz Minguez,Laia Cabellos,Judit Peix,Myron Schwartz,Vincenzo Mazzaferro,Jordi Bruix,Josep M. Llovet +15 more
TL;DR: Induction of activation of IGF signaling in HCC was significantly associated with mTOR signaling and was clearly enriched in the Proliferation subclass of the molecular classification of HCC, providing the rationale for testing this therapy in clinical trials.